Last week, Fresenius Kabi announced the launch of STIMUFEND (pegfilgrastim-fpgk), a biosimilar to Amgen’s NEULASTA, in the United States. As we previously reported, STIMUFEND was Fresenius Kabi ...

In recent years, Cinfa Biotech used its resources to advance B12019, a biosimilar copy of Amgen’s chemotherapy-induced neutropenia drug Neulasta, through clinical trials. B12019 and Neulasta are ...

Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following approval late last year. This is Napp’s first launch of a product developed ...

Over the years, we have created a portfolio of biosimilar products that are being marketed in several emerging markets. “The launch of our pegfilgrastim through our collaborator in the US in ...

"The addition of the Pegfilgrastim Injection to our BIOJAMP ® portfolio reinforces our commitment to providing Canadian patients with access to high-quality, cost-effective biosimilar medications ...